Thanai Pongdee, MD

Thanai Pongdee, MD, discusses 4-year PIONEER data showing avapritinib's quality of life, symptom, and safety benefits in indolent systemic mastocytosis remain durable.

4-year PIONEER data show avapritinib sustains symptom control and improves emotional well-being and social functioning in ISM, per Thanai Pongdee, MD.

Pongdee also discussed the changing treatment landscape for indolent systemic mastocytosis and questions that will need to be answered in the field.

Pongdee discussed research presented at the AAAAI/WAO Joint Congress that focused on improving diagnosis of indolent systemic mastocytosis.